# Clinical Trials Data EGFR - Document 15

# Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01719380

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Metastatic colorectal cancer\n\* Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens\n\* Life expectancy \u2265 3 months\n\* ECOG performance status \u2264 2\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Patients with clinically manifested diabetes\n\* Acute or chronic pancreatitis\n\* Clinically significant cardiac disease\n\nOther protocol-defined inclusion/exclusion criteria may apply.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't state that an EGFR mutation is required for inclusion, nor does it list it as an exclusion criterion. Therefore, having an EGFR mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not have any of the exclusion criteria to be eligible.